MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a sustainable and enabling environment for access to innovative medicines and vaccines.
It is essential that we work closer than ever before to preserve and expand access to innovative medicines and vaccines
